Amedeo Smart

Free Medical Literature Service

 

Amedeo

Antiretroviral Therapy
  Free Subscription

Articles published in
J Infect Dis
    April 2024
  1. RIDDLER SA, Kelly CW, Hoesley CJ, Ho KS, et al
    A Phase 1 Clinical Trial to Assess the Safety and Pharmacokinetics of a Tenofovir Alafenamide/Elvitegravir Insert Administered Rectally for HIV Prevention.
    J Infect Dis. 2024 Apr 24:jiae211. doi: 10.1093.
    >> Share

  2. BEGRE L, Boyd A, Plissonnier ML, Testoni B, et al
    Circulating HBV RNA and hepatitis B core-related antigen trajectories in persons with HIV/HBV coinfection and HBsAg loss on tenofovir therapy.
    J Infect Dis. 2024 Apr 16:jiae189. doi: 10.1093.
    >> Share

    December 2023
  3. MAKAROVA N, Singletary T, Peet MM, Mitchell J, et al
    Extended post-exposure protection against vaginal SHIV infection with tenofovir alafenamide fumarate/elvitegravir inserts in macaques.
    J Infect Dis. 2023 Dec 22:jiad599. doi: 10.1093.
    >> Share

    November 2023
  4. WELD ED, McGowan I, Anton P, Fuchs EJ, et al
    Tenofovir Douche as HIV Pre-Exposure Prophylaxis for Receptive Anal Intercourse: Safety, Acceptability, Pharmacokinetics, & Pharmacodynamics (DREAM 01).
    J Infect Dis. 2023 Nov 29:jiad535. doi: 10.1093.
    >> Share

  5. ZIVICH PN, Cole SR, Edwards JK, Glidden DV, et al
    HIV prevention among men who have sex with men: tenofovir alafenamide combination preexposure prophylaxis versus placebo.
    J Infect Dis. 2023 Nov 16:jiad507. doi: 10.1093.
    >> Share

    September 2023
  6. BUTT AA, Yan P, Shaikh OS, Talisa VB, et al
    Nirmatrelvir/ritonavir Use and Hospitalizations or Death in Previously Uninfected Non-hospitalized High-risk Population with COVID-19: A matched cohort study.
    J Infect Dis. 2023 Sep 15:jiad393. doi: 10.1093.
    >> Share

    August 2023
  7. PARASKEVIS D, Gkova M, Mellou K, Gerolymatos G, et al
    Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir as treatments for COVID-19 in high-risk patients.
    J Infect Dis. 2023 Aug 11:jiad324. doi: 10.1093.
    >> Share

  8. SCEVOLA S, Niubo J, Domingo P, Verdejo G, et al
    Decay of human immunodeficiency virus (HIV) RNA in seminal plasma and rectal fluid in treatment-naive adults starting antiretroviral therapy with dolutegravir plus lamivudine or bictegravir/emtricitabine/tenofovir alafenamide.
    J Infect Dis. 2023 Aug 1:jiad304. doi: 10.1093.
    >> Share

    May 2023
  9. SCHWENKE JM, Thorball CW, Schoepf IC, Ryom L, et al
    Association of a Polygenic Risk Score with Osteoporosis in People Living with HIV: The Swiss HIV Cohort Study.
    J Infect Dis. 2023 May 24:jiad179. doi: 10.1093.
    >> Share

    December 2022
  10. DONNELLAN S, Pennington SH, Ruggiero A, Martinez-Rodriguez C, et al
    A quantitative method for the study of HIV-1 and Mycobacterium tuberculosis co-infection.
    J Infect Dis. 2022 Dec 20:jiac491. doi: 10.1093.
    >> Share

    October 2022
  11. JAO J, Sun S, Bonner LB, Legbedze J, et al
    Lower insulin sensitivity in newborns with in utero HIV and antiretroviral exposure who are uninfected in Botswana.
    J Infect Dis. 2022 Oct 14. pii: 6761332. doi: 10.1093.
    >> Share

  12. ESHLEMAN SH, Fogel JM, Halvas EK, Piwowar-Manning E, et al
    HIV RNA screening reduces integrase strand transfer inhibitor resistance risk in persons receiving long-acting cabotegravir for HIV prevention.
    J Infect Dis. 2022 Oct 14. pii: 6761331. doi: 10.1093.
    >> Share

    September 2022
  13. SMITH MSR, Mohan H, Ajaykumar A, Hsieh AYY, et al
    Second-generation HIV integrase inhibitors induce differentiation dysregulation and exert toxic effects in human embryonic stem cell and mouse models.
    J Infect Dis. 2022 Sep 19. pii: 6704757. doi: 10.1093.
    >> Share

  14. AVERY RK, Prono MVD
    Bebtelovimab in the Real World: Promise and Fulfillment.
    J Infect Dis. 2022 Sep 17. pii: 6702587. doi: 10.1093.
    >> Share

  15. RAZONABLE RR, O'Horo JC, Hanson SN, Arndt RF, et al
    Outcomes of Bebtelovimab Treatment is Comparable to Ritonavir-boosted Nirmatrelvir among High-Risk Patients with Coronavirus Disease-2019 during SARS-CoV-2 BA.2 Omicron Epoch.
    J Infect Dis. 2022 Sep 17. pii: 6702534. doi: 10.1093.
    >> Share

  16. HALL SA, Burns GS, Mooney BJ, Millen R, et al
    Hepatitis B Virus Flares following Nucleot(s)ide Analogue Cessation Are Associated with Activation of TLR Signalling Pathways.
    J Infect Dis. 2022 Sep 15. pii: 6701634. doi: 10.1093.
    >> Share

    March 2022
  17. ESHLEMAN SH, Fogel JM, Piwowar-Manning E, Chau G, et al
    Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.
    J Infect Dis. 2022 Mar 18. pii: 6549543. doi: 10.1093.
    >> Share

    February 2022
  18. SMITH RA, Wu VH, Song J, Raugi DN, et al
    Spectrum of Activity of Raltegravir and Dolutegravir Against Novel Treatment-Associated Mutations In HIV-2 Integrase: A Phenotypic Analysis Using An Expanded Panel of Site-Directed Mutants.
    J Infect Dis. 2022 Feb 3. pii: 6521074. doi: 10.1093.
    >> Share

    December 2021
  19. CHIEN-HUNG C, Peng CY, Kuo YH, Hu TH, et al
    Earlier and higher rate of hepatitis B virus relapse after discontinuing tenofovir versus entecavir in HBeAg-positive patients.
    J Infect Dis. 2021 Dec 11. pii: 6459556. doi: 10.1093.
    >> Share

  20. MASWIME S, Pule C, Mtshali Z, Chawana R, et al
    HIV, Placental Lesions, and Adverse Perinatal Outcomes.
    J Infect Dis. 2021;224.
    >> Share

    October 2021
  21. STONE M, Rosenbloom DIS, Bacchetti P, Deng X, et al
    Assessing the Suitability of Next-Generation Viral Outgrowth Assays to Measure Human Immunodeficiency Virus 1 Latent Reservoir Size.
    J Infect Dis. 2021;224:1209-1218.
    >> Share

    August 2021
  22. PALICH R, Teyssou E, Sayon S, Abdi B, et al
    Kinetics of archived M184V mutation in treatment-experienced virally suppressed HIV-infected patients.
    J Infect Dis. 2021 Aug 20. pii: 6355381. doi: 10.1093.
    >> Share

    June 2021
  23. ESTEBAN-CANTOS A, Montejano R, Rodriguez-Centeno J, Saiz-Medrano G, et al
    Longitudinal changes in epigenetic age acceleration in aviremic HIV-infected recipients of long-term antiretroviral treatment.
    J Infect Dis. 2021 Jun 24. pii: 6309028. doi: 10.1093.
    >> Share

    May 2021
  24. HSU YC, Yeh ML, Wong GL, Chen CH, et al
    Incidences and Determinants of Functional Cure during Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B.
    J Infect Dis. 2021 May 17. pii: 6276897. doi: 10.1093.
    >> Share

  25. TAMARGO JA, Hernandez-Boyer J, Teeman C, Martin HR, et al
    Immune activation: A link between food insecurity and chronic disease in people living with HIV.
    J Infect Dis. 2021 May 16. pii: 6276422. doi: 10.1093.
    >> Share

  26. MILLAR JR, Bengu N, Vieira VA, Adland E, et al
    Early initiation of antiretroviral therapy following in utero HIV infection is associated with low viral reservoirs but other factors determine subsequent plasma viral rebound.
    J Infect Dis. 2021 May 8. pii: 6272368. doi: 10.1093.
    >> Share

    April 2021
  27. BEBELL LM, Parks K, Le MH, Ngonzi J, et al
    Placental decidual arteriopathy and vascular endothelial growth factor A (VEGF-A) expression among women with and without HIV.
    J Infect Dis. 2021 Apr 21. pii: 6242421. doi: 10.1093.
    >> Share

  28. KALA S, Meteleva K, Serghides L
    ACE2, TMPRSS2 and L-SIGN expression in placentae from HIV-positive pregnancies exposed to antiretroviral therapy-implications for SARS-CoV-2 placental infection.
    J Infect Dis. 2021 Apr 21. pii: 6242371. doi: 10.1093.
    >> Share

    March 2021
  29. LOHMAN-PAYNE B, Koster J, Gabriel B, Chilengi R, et al
    Persistent Immune activation in HIV-Infected Pregnant Women Initiating cART Post Conception.
    J Infect Dis. 2021 Mar 29. pii: 6199840. doi: 10.1093.
    >> Share

  30. MARZINKE MA, Grinsztejn B, Fogel JM, Piwowar-Manning E, et al
    Characterization of HIV infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083.
    J Infect Dis. 2021 Mar 19. pii: 6178946. doi: 10.1093.
    >> Share

  31. GOUPIL DE BOUILLE J, Vigouroux C, Plessis L, Ghislain M, et al
    Factors associated with being overweight and obesity in people living with HIV on antiretroviral therapy : socio-clinical, inflammation, and metabolic markers.
    J Infect Dis. 2021 Mar 19. pii: 6178947. doi: 10.1093.
    >> Share

    February 2021
  32. AJAYKUMAR A, Zhu M, Kakkar F, Brophy J, et al
    Elevated Blood Mitochondrial DNA in Early Life Among Uninfected Children Exposed to Human Immunodeficiency Virus and Combination Antiretroviral Therapy in utero.
    J Infect Dis. 2021;223:621-631.
    >> Share

    December 2020
  33. MANION M, Dulanto Chiang A, Pei L, Wong CS, et al
    Disseminated Mycobacterium marinum in HIV unmasked by Immune Reconstitution Inflammatory Syndrome.
    J Infect Dis. 2020 Dec 18. pii: 6041190. doi: 10.1093.
    >> Share

  34. KIRKEGAARD-KLITBO DM, Bendtsen F, Lundgren J, de Knegt RJ, et al
    Increased prevalence of liver fibrosis in people living with HIV without viral hepatitis compared to population controls.
    J Infect Dis. 2020 Dec 15. pii: 6035145. doi: 10.1093.
    >> Share

    November 2020
  35. BERTAGNOLIO S, Hermans L, Jordan MR, Avila-Rios S, et al
    Clinical Impact of Pretreatment Human Immunodeficiency Virus Drug Resistance in People Initiating Nonnucleoside Reverse Transcriptase Inhibitor-Containing Antiretroviral Therapy: A Systematic Review and Meta-analysis.
    J Infect Dis. 2020 Nov 17. pii: 5986606. doi: 10.1093.
    >> Share

  36. DIETRICH LG, Thorball CW, Ryom L, Burkhalter F, et al
    Rapid Progression of Kidney Dysfunction in Swiss People Living with HIV: Contribution of Polygenic Risk Score and D:A:D Clinical Risk Score.
    J Infect Dis. 2020 Nov 5. pii: 5957071. doi: 10.1093.
    >> Share

    October 2020
  37. TIRABOSCHI JM, Rojas J, Zetterberg H, Blennow K, et al
    No changes in HIV suppression and inflammatory markers in CSF in patients randomly switched to DTG + 3TC (Spanish HIV/AIDS Research Network, PreEC/RIS 62).
    J Infect Dis. 2020 Oct 13. pii: 5922599. doi: 10.1093.
    >> Share

  38. LUSCOMBE CA, Avihingsanon A, Supparatpinyo K, Gatechompol S, et al
    Human immunodeficiency virus type-1 Vpu inhibitor, BIT225, in combination with 3-drug antiretroviral therapy modulates inflammation and immune cells functions.
    J Infect Dis. 2020 Oct 10. pii: 5920638. doi: 10.1093.
    >> Share

    August 2020
  39. WU JF, Chang KC, Ni YH, Hsu HY, et al
    Impacts of the percentage of basal core promoter mutation on the progression of liver fibrosis after HBeAg-seroconversion.
    J Infect Dis. 2020 Aug 29. pii: 5899201. doi: 10.1093.
    >> Share

  40. GANDHI RT, Cyktor JC, Bosch RJ, Mar H, et al
    Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy.
    J Infect Dis. 2020 Aug 21. pii: 5895496. doi: 10.1093.
    >> Share

    July 2020
  41. OVERTON ET, Kantor A, Fitch KV, Muntner P, et al
    An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency Virus.
    J Infect Dis. 2020;222.
    >> Share

  42. PINTYE J, Huo Y, Kacanek D, Zhang K, et al
    Extent of in-utero transfer of tenofovir from mother to fetus: a paired analysis of hair specimens collected at birth from a cohort in the United States.
    J Infect Dis. 2020 Jul 4. pii: 5867166. doi: 10.1093.
    >> Share

    June 2020
  43. WAGNER AD, Kinuthia J, Dettinger J, Mwongeli N, et al
    Challenges of discrepant HIV tests in pregnant women in the PrEP era - to treat or not to treat?
    J Infect Dis. 2020 Jun 19. pii: 5860162. doi: 10.1093.
    >> Share

    May 2020
  44. ANTHONY DD, Sulkowski MS, Smeaton LM, Damjanovska S, et al
    HCV DAA Therapy in Persons with HIV-HCV Genotype 1 Coinfection Results in High Rate of Sustained Virologic Response and Heterogeneity in Normalization of Soluble Markers of Immune Activation.
    J Infect Dis. 2020 May 15. pii: 5836999. doi: 10.1093.
    >> Share

  45. CHANG WY, Chiu YC, Chiu FW, Hsu YC, et al
    High Risk of clinical relapse in HBV-infected patients after cessation of prophylactic antiviral therapy for rituximab-containing chemotherapy.
    J Infect Dis. 2020 May 12. pii: 5836326. doi: 10.1093.
    >> Share

  46. WANG Y, Liu Y, Liu L, Wang X, et al
    Clinical Outcomes in 55 Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Who Were Asymptomatic at Hospital Admission in Shenzhen, China.
    J Infect Dis. 2020;221:1770-1774.
    >> Share

    April 2020
  47. DEFILIPPI C, Toribio M, Wong LP, Sadreyev R, et al
    Differential Plasma Protein Regulation and Statin Effects in HIV-infected and Non-HIV-infected Patients Utilizing a Proteomics Approach Protein Regulation and Statin Effects in HIV.
    J Infect Dis. 2020 Apr 20. pii: 5822753. doi: 10.1093.
    >> Share

    March 2020
  48. FAN R, Peng J, Xie Q, Tan D, et al
    Combining HBV RNA and hepatitis B core-related antigen: guidance for safely stopping nucleos(t)ide analogues in HBeAg-positive chronic hepatitis B patients.
    J Infect Dis. 2020 Mar 25. pii: 5811444. doi: 10.1093.
    >> Share

  49. BALAGOPAL A, Smeaton LM, Quinn J, Venuto CS, et al
    Intrahepatic Viral Kinetics during Direct-Acting Antivirals for Hepatitis C in HIV Co-infection:The ACTG A5335S Substudy.
    J Infect Dis. 2020 Mar 23. pii: 5810960. doi: 10.1093.
    >> Share

  50. SURIAL B, Ledergerber B, Calmy A, Cavassini M, et al
    Changes in renal function after switching from TDF to TAF in HIV-infected individuals: a prospective cohort study.
    J Infect Dis. 2020 Mar 19. pii: 5809951. doi: 10.1093.
    >> Share

  51. DOBARD C, Makarova N, Nishiura K, Dinh C, et al
    Cabotegravir long-acting protects macaques against repeated penile SHIV exposures.
    J Infect Dis. 2020 Mar 4. pii: 5780064. doi: 10.1093.
    >> Share

    February 2020
  52. COSTA C, Scabini S, Kaimal A, Kasozi W, et al
    Calcaneal quantitative ultrasound and urine retinol binding protein in HIV-positive antiretroviral-treated patients in Uganda: a pilot study.
    J Infect Dis. 2020 Feb 28. pii: 5766432. doi: 10.1093.
    >> Share

  53. KNUDSEN AD, Krebs-Demmer L, Bjorge NID, Elming MB, et al
    Pericardial adipose tissue volume is independently associated with HIV status and prior use of stavudine, didanosine or indinavir.
    J Infect Dis. 2020 Feb 6. pii: 5728662. doi: 10.1093.
    >> Share

  54. BROWN TT, Moser C, Currier JS, Ribaudo HJ, et al
    Erratum to: Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
    J Infect Dis. 2020 Feb 5. pii: 5727535. doi: 10.1093.
    >> Share

    January 2020
  55. DEZANET LNC, Maylin S, Gabassi A, Rougier H, et al
    Kinetics of hepatitis B core-related antigen and anti-hepatitis B core antibody and their association with serological response in HIV-hepatitis B co-infection.
    J Infect Dis. 2020 Jan 21. pii: 5710864. doi: 10.1093.
    >> Share

    December 2019
  56. PHILLIPS A, Cambiano V, Johnson L, Nakagawa F, et al
    Potential impact and cost-effectiveness of condomless-sex-concentrated PrEP in KwaZulu-Natal accounting for drug resistance.
    J Infect Dis. 2019 Dec 18. pii: 5680588. doi: 10.1093.
    >> Share

  57. TRIANT VA, Siedner MJ
    Darunavir and Cardiovascular Risk: Evaluating the Data to Inform Clinical Care.
    J Infect Dis. 2019 Dec 11. pii: 5673540. doi: 10.1093.
    >> Share

  58. COSTAGLIOLA D, Potard V, Lang S, De Castro N, et al
    Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIV.
    J Infect Dis. 2019 Dec 11. pii: 5673542. doi: 10.1093.
    >> Share

    November 2019
  59. GREGSON J, Rhee SY, Datir R, Pillay D, et al
    HIV-1 viral load is elevated in individuals with reverse transcriptase mutation M184V/I during virological failure of first line antiretroviral therapy and is associated with compensatory mutation L74I.
    J Infect Dis. 2019 Nov 27. pii: 5644529. doi: 10.1093.
    >> Share

  60. FLYS T, Nissley DV, Claasen CW, Jones D, et al
    Erratum to: Sensitive Drug-Resistance Assays Reveal Long-Term Persistence of HIV-1 Variants with the K103N Nevirapine (NVP) Resistance Mutation in Some Women and Infants after the Administration of Single-Dose NVP: HIVNET 012.
    J Infect Dis. 2019 Nov 27. pii: 5644562. doi: 10.1093.
    >> Share

  61. KURITZKES DR
    New perspectives on the virologic consequences of M184V or I in HIV-1 Reverse Transcriptase.
    J Infect Dis. 2019 Nov 27. pii: 5644530. doi: 10.1093.
    >> Share

  62. TENG MN, Mejias A, Ramilo O, Peeples ME, et al
    Live Attenuated Vaccine with a Stabilized Mutation and Gene Deletion for Prevention of Respiratory Syncytial Virus Disease in Young Children.
    J Infect Dis. 2019 Nov 23. pii: 5638037. doi: 10.1093.
    >> Share

  63. SMITH C, Moraka NO, Ibrahim M, Moyo S, et al
    HIV Exposure but Not Early CMV Infection is Associated with Increased Hospitalization and Decreased Memory T-cell Responses to Tetanus Vaccine.
    J Infect Dis. 2019 Nov 10. pii: 5618838. doi: 10.1093.
    >> Share

  64. KOVACS AAZ, Kono N, Wang CH, Wang D, et al
    Association of HLA Genotype With T-Cell Activation in Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus-Coinfected Women.
    J Infect Dis. 2019 Nov 10. pii: 5618844. doi: 10.1093.
    >> Share

    October 2019
  65. CHIHOTA BV, Wandeler G, Chilengi R, Mulenga L, et al
    High Rates of Hepatitis B Virus (HBV) Functional Cure Among Human Immunodeficiency Virus-HBV Coinfected Patients on Antiretroviral Therapy in Zambia.
    J Infect Dis. 2019 Oct 15. pii: 5581876. doi: 10.1093.
    >> Share

    August 2019
  66. DEE L, Boone CA, Palm D, Campbell D, et al
    Secondary HIV Infection and Mitigation in Cure-Related HIV Trials During Analytical Treatment Interruptions.
    J Infect Dis. 2019;220:1230-1231.
    >> Share

    March 2019
  67. COSTANTINI S, Walensky RP
    The Costs of Drugs in Infectious Diseases: Branded, Generics, and Why We Should Care.
    J Infect Dis. 2019 Mar 19. pii: 5385524. doi: 10.1093.
    >> Share

  68. LELIEVRE JD
    Preexposure Prophylaxis for Mitigating Risk of HIV Transmission During HIV Cure-Related Clinical Trials With a Treatment Interruption.
    J Infect Dis. 2019 Mar 12. pii: 5376539. doi: 10.1093.
    >> Share

    February 2019
  69. SORTINO O, Huppler Hullsiek K, Richards E, Rupert A, et al
    The Effects of Recombinant Human Lactoferrin on Immune Activation and the Intestinal Microbiome Among People Living with HIV Receiving Antiretroviral Therapy.
    J Infect Dis. 2019 Feb 4. pii: 5306488. doi: 10.1093.
    >> Share

    January 2019
  70. SINGH A, Prasad S
    The Immune Checkpoint Protein Programmed Death 1 During HIV Infection in Children: Clinical Relevance and Beyond.
    J Infect Dis. 2019 Jan 8. pii: 5280901. doi: 10.1093.
    >> Share

  71. KAPLAN D
    Causal Inference for Observational Studies.
    J Infect Dis. 2019;219:1-2.
    >> Share

    September 2018
  72. GUPTA SK, Liu Z, Sims EC, Repass MJ, et al
    Endothelial Colony Forming Cell Function Is Reduced in HIV.
    J Infect Dis. 2018 Sep 18. pii: 5099934. doi: 10.1093.
    >> Share

    July 2018
  73. JARVIS JN, Harrison TS
    Understanding Causal Pathways in Cryptococcal Meningitis Immune Reconstitution Inflammatory Syndrome.
    J Infect Dis. 2018 Jul 16. pii: 5054279. doi: 10.1093.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016